Categorical weight loss A total of 93.1% ( n = 27) of participants in the placebo group lost less than 10% weight loss, compared to 14.7% ( n = 5) in the semaglutide group
This membership offers benefits like unlimited consultations with obesity specialists, personalized care plans, access to a mobile health app, functional nutrition coaching, and access to Ivim Healths prior authorization team to assist with insurance approvals
A 2016 study suggested visible results in just three sessions, and a 67 percent reduction in cellulite
Semaglutide, a long-acting GLP-1 agonist, exhibited a sustained weight decrease of approximately 15% of body weight in clinical studies, whereas tirzepatide, a combination GIP/GLP-1 agonist, attained a weight loss of up to 22.5% in the SURMOUNT trials [36,37]